Selank vs Semax: A Research-Use Comparison of Two Russian Regulatory Neuropeptides
Two synthetic heptapeptides from the same Soviet-era programme, built on different parent molecules and studied along sharply divergent mechanistic lines.
Selank is a synthetic tuftsin analogue studied mainly in anxiety, GABAergic, and immunomodulatory models, while Semax is a synthetic ACTH(4-10) analogue studied mainly in neuroprotection, neurotrophin, and cognition models. They share a Russian regulatory-peptide lineage but differ in parent peptide and the mechanisms investigated preclinically. For research use only.
They are almost always named in the same breath, yet Selank and Semax have less in common than their shared reputation suggests. Both are synthetic “regulatory neuropeptides” engineered in late-Soviet and post-Soviet Russia, where each has been studied for decades; both carry the same C-terminal trick for surviving enzymes in the bloodstream. But they descend from entirely different parent molecules, and the published science has chased them down largely separate corridors. The interesting question is not which is stronger, but which maps to your experimental question. Both products are supplied strictly for research use only (RUO): in vitro / in-laboratory use, not for human or veterinary consumption, and nothing below should be read as a dosing, administration, or treatment recommendation.
What are Selank and Semax, and where do they come from?
Selank is a synthetic heptapeptide analogue of the immunoactive endogenous fragment tuftsin, extended with a C-terminal stabilizing sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) to slow enzymatic degradation.1 It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences together with the Zakusov Institute of Pharmacology, and in Russia it has been described in the regulatory literature as a peptide anxiolytic. The Condor Research catalogue lists Selank as a single-peptide 10 mg/vial lyophilized powder (Selank product page).
Semax is a synthetic heptapeptide based on the ACTH(4-10) (melanocortin) fragment, extended with a Pro-Gly-Pro tail (Met-Glu-His-Phe-Pro-Gly-Pro) that confers proteolytic stability while removing the classic corticotropic hormonal activity of ACTH.8 It emerged from the same Russian research environment and has been studied extensively in neuroprotection and cognition models. Condor lists Semax as a single-peptide 10 mg/vial lyophilized powder (Semax product page), and also offers a combined Semax + Selank research blend (20 mg/vial) for researchers who wish to study the two side by side.
How do their chemistry and specifications differ?
The core distinction is the parent peptide: Selank derives from tuftsin, an immunopeptide,1 whereas Semax derives from ACTH(4-10), a melanocortin fragment.8 That single fact propagates outward into the directions each research programme has taken. The table below summarizes the catalogue specifications and the lines of investigation each compound is associated with in the literature.
| Attribute | Selank | Semax |
|---|---|---|
| Chemical class | Synthetic heptapeptide; tuftsin analogue (immunopeptide lineage) | Synthetic heptapeptide; ACTH(4-10) / melanocortin analogue |
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| Parent / origin | Tuftsin fragment + C-terminal PGP stabilizer (Russian regulatory-peptide program) | ACTH(4-10) fragment + C-terminal PGP stabilizer (Russian regulatory-peptide program) |
| Mechanisms investigated (preclinical) | GABAergic gene expression, BDNF in hippocampus/cortex, enkephalin/monoamine modulation, immunomodulation | BDNF/NGF neurotrophin expression, neuroprotection in ischemia models, melanocortin signaling, copper-amyloid interaction |
| Predominant research themes | Anxiety/anxiolytic models, stress, alcohol/withdrawal behavior, immune markers | Neuroprotection, cognition, ischemic-stroke models, antidepressant-like stress models |
| Format (Condor) | 10 mg/vial white lyophilized powder, ≥99% HPLC | 10 mg/vial white lyophilized powder, ≥99% HPLC |
| Characterization | HPLC purity; third-party COA referenced for catalogue items | HPLC purity; third-party tested with COA |
| Category (Condor) | Neuropeptides / Peptides in Vials | Neuropeptides / Peptides in Vials |
Catalogue specifications and predominant lines of preclinical investigation for Selank and Semax.
What does the preclinical literature say about Selank?
Most published Selank work sits in behavioral and molecular neuropharmacology. In cell-based work, Selank altered the expression of genes involved in GABAergic neurotransmission in IMR-32 neuroblastoma cells, alongside GABA and olanzapine comparators.2 In rodent models, it has been reported to influence BDNF content in the hippocampus and prefrontal cortex in an ethanol-related memory-impairment paradigm,3 and to potentiate the anxiolytic effect of diazepam under unpredictable chronic mild stress.4 A mechanistic review frames Selank’s activity around its tuftsin-derived structure and proteolytic stability,1 tying the behavioural readouts back to the molecule that the C-terminal extension was built to preserve.
What does the preclinical literature say about Semax?
Semax research is concentrated in neurotrophin signaling and neuroprotection. Transcriptomic work in cerebral ischemia-reperfusion models has examined how ACTH-like and glyproline peptides shift inflammatory and neurosignaling gene expression after experimental stroke.7 A distinct physical-chemistry line of work found that Semax affects copper-induced amyloid-beta aggregation in artificial membrane models,6 a mechanistic register entirely absent from the Selank literature. Semax has also been examined in antidepressant-like and antistress rodent paradigms as an ACTH(4-10) analogue, alongside a melanocortin comparator.8
7 of the most-cited reference papers behind this comparison are preclinical in vitro or animal studies; only the remaining few report clinical data, and those are small, single-region, and outside EU/US regulatory frameworks.
How strong is the clinical evidence, really?
For honest research framing it is essential to separate the large preclinical base from the far thinner clinical one. The mechanistic and behavioral findings above are preclinical. Both peptides also appear in Russian-language clinical reports — for Selank, in generalized anxiety and neurasthenia populations,5 and for Semax in patients at different stages of ischemic stroke.10 These clinical papers are mostly small, single-region, and conducted outside the regulatory frameworks used in the EU and US; neither compound is an approved drug in those jurisdictions. The clinical signal should be treated as preliminary and geographically concentrated, and never extrapolated to human use.
Two molecules can share a lineage and a stabilising tail and still be the wrong tools for each other’s questions. Selank and Semax are studied as a related pair precisely because they are mechanistically distinct.
That distinction has been examined head-on: a functional-connectomic study compared Selank and Semax effects directly, underscoring that they are best understood as related but separable research tools rather than interchangeable ones.9
Which one is relevant for a given research question?
Neither is “better” in the abstract — they map to different experimental questions. Investigators modeling anxiety-like behavior, GABAergic signaling, stress, or immunomodulation will find more directly relevant Selank literature.24 Investigators modeling neuroprotection, neurotrophin expression, ischemia, or cognition will find more Semax literature.67 Their shared C-terminal Pro-Gly-Pro stabilization and common research lineage are why they are often handled as a pair, and why a side-by-side blend exists for comparative in vitro work.
Both compounds are supplied by Condor Research as white lyophilized powders, 10 mg per vial, at ≥99% purity by HPLC, with third-party testing and a COA referenced for catalogue items. They are neuropeptides in the Peptides in Vials category, intended strictly for research use only with no human-use directions provided. Internal references: Selank (10 mg/vial) · Semax (10 mg/vial) · Semax + Selank blend (20 mg/vial).
- Selank and Semax are both synthetic heptapeptides from the same Russian regulatory-peptide programme, but derive from different parents: tuftsin (Selank) versus ACTH(4-10) (Semax).
- Selank's preclinical literature clusters around GABAergic signalling, BDNF modulation, and immune markers; Semax's clusters around neurotrophin expression, neuroprotection in ischaemia, and melanocortin signalling.
- Both share a C-terminal Pro-Gly-Pro stabiliser that slows enzymatic degradation, which is why they are often handled as a pair and offered as a comparative blend.
- Neither is universally "better": the choice maps to the experimental question, not to any claim of human efficacy.
- The rigorous evidence base is overwhelmingly preclinical; the clinical literature is small, largely Russian-language, single-region, and outside EU/US regulatory frameworks, and neither compound is an approved drug there.
- Both are supplied strictly for research use only, as ≥99% HPLC lyophilized powders with third-party COA referenced.
What is the core difference between Selank and Semax?
Selank is a synthetic analogue of tuftsin (an immunopeptide) studied largely in anxiety, GABAergic, and immunomodulation models. Semax is a synthetic analogue of ACTH(4-10) (a melanocortin fragment) studied largely in neuroprotection, BDNF/NGF expression, and cognition/ischemia models. Different parent peptides, different research directions. Both are research use only.
Selank vs Semax: which is better for research?
Neither is universally better; the right choice depends on the experimental question. Selank has more literature in anxiety-like and GABAergic/immunomodulatory paradigms, while Semax has more in neurotrophin (BDNF/NGF) and neuroprotection/ischemia paradigms. This is an experimental-design consideration for in vitro/animal work only, not a comparison of human efficacy.
Do Selank and Semax share the same mechanism of action?
No. Their published preclinical mechanisms differ. Selank work centers on GABAergic gene expression, BDNF modulation, and immune markers; Semax work centers on neurotrophin expression, melanocortin-related signaling, neuroprotection in ischemia models, and copper-amyloid interaction. They share a Russian regulatory-peptide lineage and a stabilizing Pro-Gly-Pro C-terminus, not an identical mechanism.
Is the clinical evidence for Selank and Semax strong?
The clinical literature exists but is limited. Most clinical reports are small, Russian-language, single-region studies (e.g., Selank in anxiety/neurasthenia; Semax in ischemic stroke) conducted outside EU/US regulatory frameworks. Neither is an approved drug in the EU or US. The bulk of the rigorous data is preclinical (in vitro and animal); clinical findings should be treated as preliminary.
Why does Condor offer a combined Semax + Selank product?
Because the two peptides are mechanistically distinct but historically studied as a pair, a combined 20 mg/vial blend (Semax 10 mg + Selank 10 mg) is offered to support comparative in vitro research where investigators want both tools side by side. Like the single-peptide vials, the blend is supplied strictly for research use only.
How are Selank and Semax supplied and characterized?
Both are supplied by Condor Research as white lyophilized powders, 10 mg per vial, at greater than or equal to 99% purity by HPLC, with third-party testing and a COA referenced for catalogue items. They are neuropeptides in the Peptides in Vials category, intended for research use only with no human-use directions provided.